Longitudinal association of type 2 diabetes and insulin therapy with muscle parameters in the KORA-Age study
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Aims The aim of the current study was to investigate the association of type 2 diabetes (T2D) and insulin treatment with changes in muscle mass, muscle strength, and physical performance in older adults.Methods In 731 participants of the population-based KORA-Age study aged 74.6 ± 6.2 years (T2D: n = 118; insulin treatment: n = 20), skeletal muscle index (SMI [kg/m 2]), hand grip strength (GS [kg]), and a timed up and go test (TUG [s]) were performed at baseline and after a follow-up time of 3 years. The association of T2D and insulin therapy with changes in muscle parameters was analyzed using linear regression models.Results After adjustment for sex, age, BMI, physical activity, smoking, and multimorbidity, T2D was associated with the change in SMI during follow-up (β - 0.1 (95% CI - 0.3 to - 0.02) kg/m 2; p = 0.02), but not with a change in GS (β - 0.9 (95% CI - 1.9 to 0.04) kg) or TUG (β - 0.1 (95% CI - 0.7 to 0.5) s). Insulin therapy was positively associated with change in SMI (β 0.6 (95% CI 0.3-0.9) kg/m 2; p = 0.001), but not in GS (β - 1.6 (95% CI - 4.1 to 0.8) kg) or TUG (β 1.6 (95% CI - 0.2-3.4) s) in comparison with treatment with oral anti-diabetic medication alone.Conclusions Participants with T2D showed an accelerated decline in muscle mass compared to non-diabetic participants. Insulin therapy was associated with preserved muscle mass, but not muscle function parameters, indicating a discrepancy between muscle mass and function in this high-risk population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While existing clinical trial and epidemiological data demonstrate a positive correlation between insulin use and measures related to sarcopenia,43–45”
From Imaging of Sarcopenia in Type 2 Diabetes Mellitus (2024) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimation of skeletal muscle mass by bioelectrical impedance analysis
Janssen, I., Heymsfield, S. B., Baumgartner, R. N., & Ross, R. (2000) · Journal of Applied Physiology · doi:10.1152/jappl.2000.89.2.465 · Cited by 1,482
Anabolic signaling deficits underlie amino acid resistance of wasting, aging muscle
Cuthbertson, D., Smith, K., Babraj, J., Leese, G., Waddell, T., Atherton, P., Wackerhage, H., Taylor, P. M., & Rennie, M. J. (2005) · The FASEB Journal · doi:10.1096/fj.04-2640fje · Cited by 1,211
Insulin effects in muscle and adipose tissue
Dimitriadis, G., Mitrou, P., Lambadiari, V., Maratou, E., & Raptis, S. A. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(11)70014-6 · Cited by 649
Sarcopenia and type 2 diabetes mellitus: a bidirectional relationship
Mesinovic, J., Zengin, A., De Courten, B., Ebeling, P. R., & Scott, D. (2019) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s186600 · Cited by 553
The physical activity scale for individuals with physical disabilities: Development and evaluation
Washburn, R. A., Zhu, W., McAuley, E., Frogley, M., & Figoni, S. F. (2002) · Archives of Physical Medicine and Rehabilitation · doi:10.1053/apmr.2002.27467 · Cited by 458
Insulin resistance of muscle protein metabolism in aging
Rasmussen, B. B., Fujita, S., Wolfe, R. R., Mittendorfer, B., Roy, M., Rowe, V. L., & Volpi, E. (2006) · The FASEB Journal · doi:10.1096/fj.05-4607fje · Cited by 402
Oberbach, A., Bossenz, Y., Lehmann, S., Niebauer, J., Adams, V., Paschke, R., Schön, M. R., Blüher, M., & Punkt, K. (2006) · Diabetes Care · doi:10.2337/diacare.29.04.06.dc05-1854 · Cited by 385
Phielix, E., Schrauwen-Hinderling, V. B., Mensink, M., Lenaers, E., Meex, R., Hoeks, J., Kooi, M. E., Moonen-Kornips, E., Sels, J.-P., Hesselink, M. K. C., et al. (2008) · Diabetes · doi:10.2337/db08-0391 · Cited by 359
Intramuscular adipose tissue, sarcopenia, and mobility function in older individuals
Marcus, R. L., Addison, O., Dibble, L. E., Foreman, K. B., Morrell, G., & LaStayo, P. (2012) · Journal of Aging Research · doi:10.1155/2012/629637 · Cited by 296
Role of muscle mass and muscle quality in the association between diabetes and gait speed
Volpato, S., Bianchi, L., Lauretani, F., Lauretani, F., Bandinelli, S., Guralnik, J. M., Zuliani, G., & Ferrucci, L. (2012) · Diabetes Care · doi:10.2337/dc11-2202 · Cited by 294
Cited by
Perturbed BMP signaling and denervation promote muscle wasting in cancer cachexia
Sartori, R., Hagg, A., Zampieri, S., Armani, A., Winbanks, C. E., Viana, L. R., Haidar, M., Watt, K. I., Qian, H., Pezzini, C., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.aay9592 · Cited by 167
Massimino, E., Izzo, A., Riccardi, G., & Della Pepa, G. (2021) · Cells · doi:10.3390/cells10081958 · Cited by 102
“Epidemiological evidence and the clinical trial available suggest the beneficial association between insulin use and parameters of sarcopenia [87,95,96], indicating that a possible prescription of exogenous insulin could improve insulin signaling in the skeletal muscle, promote protein synthesis, and protect against t…”
BackgroundAnti‐diabetic drugs and sarcopenia: emerging links, mechanistic insights, and clinical implications
Zhang, X., Zhao, Y., Chen, S., & Shao, H. (2021) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12838 · Cited by 92
“More recently, a longitudinal study of insulin therapy with changes in muscle parameters showed that insulin preserved muscle mass, but not muscle function as assessed by hand grip strength.(25) However, it is noteworthy that several early clinical studies examining insulin therapy and body composition have shown that…”
BackgroundHou, Y., Xiang, J., Wang, B., Duan, S., Song, R., Zhou, W., Tan, S., & He, B. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1263650 · Cited by 82
Vendrell, C. S., Tercero, E. G., Hernández, J. B. M., & Cedeño‐Veloz, B. A. (2023) · Nutrients · doi:10.3390/nu15194149 · Cited by 55
“These drugs vary in their (Figure 3): While numerous studies have attempted to evaluate the effects of glucose-lowering medications on sarcopenia While numerous studies have attempted to evaluate the effects of glucose-lowering medications on sarcopenia [ [ 20 20 – –41 41 ], ], these these levels.”
BackgroundOmura, T., & Araki, A. (2022) · Geriatrics & Gerontology International · doi:10.1111/ggi.14339 · Cited by 47
Sinclair, A. J., Pennells, D., & Abdelhafiz, A. H. (2022) · Aging Clinical and Experimental Research · doi:10.1007/s40520-022-02142-8 · Cited by 48
“2) years, insulin therapy was associated with preserved muscle mass, but not muscle function parameters [159].”
BackgroundWitham, M. D., Granic, A., Pearson, E. R., Robinson, S. M., & Sayer, A. A. (2023) · Drugs & Aging · doi:10.1007/s40266-023-01042-4 · Cited by 49
“…between insulin use and a slower decline in skeletal muscle mass measured by bioimpedance over a 3-year follow-up period was found in a cohort of older people in Augsburg, Germany [173], although measures of muscle function (grip strength and timed up and go) did not show comparable benefit.”
BackgroundMetabolic Impact of Frailty Changes Diabetes Trajectory
Sinclair, A. J., & Abdelhafiz, A. H. (2023) · Metabolites · doi:10.3390/metabo13020295 · Cited by 46
The Current Landscape of Pharmacotherapies for Sarcopenia
Bahat, G., & Özkök, S. (2024) · Drugs & Aging · doi:10.1007/s40266-023-01093-7 · Cited by 48
“…study including 731 older adults, revealed that T2DM was independently associated with a decline in skeletal muscle index (adjusted for height 2 ), and insulin therapy was associated with preserved muscle mass, but not muscle function parameters like gait speed or Timed Up-and-Go Test [211].”
Factors associated with handgrip strength across the life course: A systematic review
Ribeiro, L. W., Berndt, S., Mielke, G. I., Doust, J. A., & Mishra, G. D. (2024) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13586 · Cited by 48
Tack, W., Cock, A. D., Dirinck, E. L., Bastijns, S., Ariën, F., & Perkisas, S. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15321 · Cited by 42
“115 Sulphonylureas, on the other hand, are suggested to have negative effects on muscle mass via stimulating atrophic signalling by inhibiting ATP-sensitive potassium channels.”
BackgroundCurrent Nutritional and Pharmacological Approaches for Attenuating Sarcopenia
Sakuma, K., Hamada, K., Yamaguchi, A., & Aoi, W. (2023) · Cells · doi:10.3390/cells12192422 · Cited by 39
“In addition, a 3-year follow-up study of 118 diabetic patients has shown that insulin produces a positive effect on skeletal muscle mass compared with other oral hypoglycemic agents [99].”
BackgroundAssociation between type 2 diabetes and chronic low back pain in general practices in Germany
Jacob, L., Rathmann, W., Koyanagi, A., Haro, J. M., & Kostev, K. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002426 · Cited by 39
Hiromine, Y., Noso, S., Rakugi, H., Sugimoto, K., Takata, Y., Katsuya, T., Fukuda, M., Akasaka, H., Osawa, H., Tabara, Y., et al. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13882 · Cited by 36
Alfaro-Alvarado, F. A., Rosas-Barrientos, J. V., Ocharan-Hernández, M. E., Díaz-Chiguer, D. L., & Vargas‐De‐León, C. (2023) · Diseases · doi:10.3390/diseases11040175 · Cited by 36
Association of sarcopenia with a higher risk of infection in patients with type 2 diabetes
Zhang, Y., Weng, S., Huang, L., Shen, X., Zhao, F., & Yan, S. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3478 · Cited by 34
“56 times that of healthy population.(5) Studies have shown that decreased muscle mass is associated with chronic complications of type 2 diabetes, such as diabetic nephropathy, diabetic peripheral neuropathy, and diabetic macrovascular disease.”
BackgroundHamasaki, H. (2021) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2021.1967743 · Cited by 28
“, 2020 [40] N = 731 (371 men and 360 women), 118 patients with T2D Age: men, 74.”
MethodSarcopenia in elderly diabetes
Wen, C., Lien, A. S., & Jiang, Y. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13752 · Cited by 25
Park, S., Kim, S., & Shin, J. Y. (2021) · Journal of Diabetes · doi:10.1111/1753-0407.13216 · Cited by 21
The crosstalk between BAT thermogenesis and skeletal muscle dysfunction
Chen, Y., Hu, Q., Wang, C., & Wang, T. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1132830 · Cited by 19
“Thus, insulin treatment may attenuate the progression of sarcopenia in patients with T2DM (Bouchi et al., 2017).”
BackgroundInfluentialAbdelhafiz, A. H., Keegan, G. L., & Sinclair, A. J. (2023) · Metabolites · doi:10.3390/metabo13060705 · Cited by 16
Understanding Insulin Actions Beyond Glycemic Control: A Narrative Review
Riachi, R., Khalife, E., Kędzia, A. W., & Niechciał, E. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14145039 · Cited by 20
“Sarcopenia, which is defined as a progressive skeletal muscle disorder that leads to muscle atrophy and weakness [45], is strongly associated with T2D [46,47].”
Insulin in Frail, Older People with Type 2 Diabetes—Low Threshold for Therapy
Abdelhafiz, A. H., Bisht, S., Kovacevic, I., Pennells, D., & Sinclair, A. J. (2022) · Diabetology · doi:10.3390/diabetology3020028 · Cited by 14
Manzano, M., Girón, M. D., Salto, R., Burgio, C., Reinoso, A., Cabrera, E., Rueda, R., & López-Pedrosa, J. M. (2023) · Nutrients · doi:10.3390/nu15224706 · Cited by 13
“Glucose-lowering drugs, such as insulin [12], metformin [13], and thiazolidine-diones [14], improve insulin sensitivity and might have a beneficial effect on parameters of sarcopenia.”
Imaging of Sarcopenia in Type 2 Diabetes Mellitus
Wang, D., Zhang, G., Yu, Y., & Zhang, Z. (2024) · Clinical Interventions in Aging · doi:10.2147/cia.s443572 · Cited by 11
Correlates of Skeletal Muscle Mass and Differences Between Novel Subtypes in Recent-Onset Diabetes
Herder, C., Maalmi, H., Saatmann, N., Zaharia, O., Straßburger, K., Burkart, V., Norman, K., & Roden, M. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad605 · Cited by 11
Bujdei-Tebeică, I., Mihai, D. A., Stoian, A. P., Ștefan, S., Stoicescu, C. I., & Serafinceanu, C. (2025) · Medicina · doi:10.3390/medicina61081399 · Cited by 11
“Another cohort study (KORA-Age) reported that older adults with T2D on insulin treatment preserved their skeletal muscle index at 3 years compared with oral agent alone therapy, although preservation did not extend to muscle function (measured by grip strength or a Timed Up and Go test) [29].”
Proteomics of the phase angle: Results from the population-based KORA S4 study
Huemer, M., Petrera, A., Hauck, S. M., Drey, M., Peters, A., & Thorand, B. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2022.06.038 · Cited by 9
Self-citationNutritional Approach to Diabetic Sarcopenia: A Comprehensive Review
Kılınç, G. E., & Vergi, Y. (2025) · Current Nutrition Reports · doi:10.1007/s13668-025-00637-0 · Cited by 11
“Another study found that insulin helped preserve muscle mass but had no effect on muscle function assessed by handgrip strength [ 110 ].”
Yang, D., Zhao, H., Lei, R., Li, Y., Zhou, X., Yuan, F., Jiang, Y., & Liu, M. (2023) · Iranian Journal of Public Health · doi:10.18502/ijph.v52i8.13404 · Cited by 14
Chen, Y., Yang, L., Gao, X., Tang, A., Hang, H., Xiong, C., Xu, F., & Sun, C. (2023) · Global Spine Journal · doi:10.1177/21925682231206962 · Cited by 8
“…neuropathy, and malnutrition may contribute to amyotrophy, leading to an accelerated loss of muscle and a slower recovery rate in patients with DM. 37,38 Secondly, DM is known to cause microvascular complications, diabetic neuropathy, and nerve damage, which further impede the recovery process.”
Zou, S., Xiao, T., Liu, M., Li, Z., Mou, X., & Lai, J. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01504-5 · Cited by 8
Taşkent, İ., Ece, B., & Aydın, S. (2024) · Tomography · doi:10.3390/tomography10070079 · Cited by 7
Bertrand, R., Lambare, B., & Andréelli, F. (2022) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2022.07.001 · Cited by 5
Association between metabolism and low back pain: a cross-sectional study
Wang, X., Tian, L., Xu, Q., Pan, X. T., Kong, L., & Zhao, H. (2025) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-025-06218-9 · Cited by 3
“Furthermore, individuals with T2DM exhibit accelerated sarcopenic progression compared to non-diabetic counterparts [42] and trunk muscle weakness may favor the occurrence of low back pain [43].”
Genton, L., Sanz, M. L., Arvanitakis, M., Ballesteros-Pomar, M. D., Bally, L., Barazzoni, R., Betry, C., Burgos, R., Cuerda, C., Hadefi, A., et al. (2025) · Clinical Nutrition · doi:10.1016/j.clnu.2025.106550 · Cited by 4
Sarcopenia in older adults: A narrative review of current concepts in diagnosis and treatment
Güngör, M., & Balcı, C. (2026) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2026.103276 · Cited by 3
Çalım, A. (2025) · International Journal of Endocrinology · doi:10.1155/ije/7492307 · Cited by 2
“While some studies suggest insulin or DPP-4 inhibitors may modulate muscle loss [20, 21], Sazlina et al. found no link between insulin sensitizers and sarcopenia risk [22].”
Tajik, A., Mahdavizadeh, V., Hadizadeh, F., & Shakour, N. (2025) · Current Diabetes Reviews · doi:10.2174/0115733998349193250207045239 · Cited by 1
Kanwar, J. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1009255 · Cited by 1
Wang, X., & Wu, X. (2026) · Science Progress · doi:10.1177/00368504261432840 · Cited by 1
Hypoglycemic drugs and sarcopenia
Dolgikh, Y. A., Bulgakova, S. V., Kurmaev, D. P., Treneva, E. V., Kosareva, O. V., Merzlova, P. Y., Sharonova, L. A., & Сергеевич, Б. А. (2025) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-228-8-216-225 · Cited by 2
Koçak, F. Ö. K., Savaş, S., & Akçiçek, S. (2021) · Ege Tıp Dergisi · doi:10.19161/etd.915688
Insulintherapie mit Erhalt der Muskelmasse bei Typ-2-Diabetes assoziiert
(2020) · Diabetologie und Stoffwechsel · doi:10.1055/a-1265-1882
Prevalence of Sarcopenia in Insulin Treated Older Adults with Type 2 DiabetesPreprint
Leite, S. A. O., Bastos, M., da Silva, M. P., Lavalle, A. C. R., Bertogy, M. C. V., Kuklik, S. C. V., & Umpierrez, G. E. (2023) · Research Square · doi:10.21203/rs.3.rs-3216192/v1
Micah Isaac Anand, W. (2023) · International Journal of Science and Research (IJSR) · doi:10.21275/sr23516191456
“As of late, a longitudinal study of insult treatment with changes in muscle parameters uncovered that insulin protected muscle mass but not muscle work as assessed by hand - hold quality [47].”
BackgroundFrailty in Older People with Diabetes Mellitus
Sinclair, A. J., & Abdelhafiz, A. H. (2024) · Springer eBooks · doi:10.1007/978-3-031-57361-3_42
McGuigan, A. (2025) · Drugs & Therapy Perspectives · doi:10.1007/s40267-025-01141-9 · Cited by 1
“Nonetheless, studies have reported improvements in muscle mass and function of patients with type 2 diabetes mellitus (T2DM) after receiving insulin (Table 2) [21, 22], but the use of insulin to treat sarcopenia in nondiabetic patients is unlikely due to risk of hypoglycaemia [2].”
Orsi, E., Arosio, B., Gaglio, A., Resi, V., Locatelli, E., & Volpato, S. (2025) · il Diabete · doi:10.30682/ildia2502a
Zhou, Q., Liu, P., Li, L., Yin, T., Bai, H., & Li, Y. (2025) · The FASEB Journal · doi:10.1096/fj.202503502r
“A cross-sectional study showed that enhanced blood sugar regulation and insulin therapy attenuated the progression of sarcopenia [21], which was consistent with the findings of longitudinal studies [22].”
Metabolic phenotypes of frailty and the course of type 2 diabetes mellitus
Александровна, Б. Л., Bulgakova, S. V., Kurmaev, D. P., Treneva, E. V., Косарева, О. В., Merzlova, P. Y., Sharonova, L. A., Dolgikh, Y. A., Pervyshin, N. A., Сергеевич, Б. А., et al. (2025) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-235-3-236-244 · Cited by 1
Kim, S. H., Arora, I., Agyemang, C. O., Anjana, R. M., Åsvold, B. O., Blom, M. T., Bhupathiraju, S. N., Bonnefond, A., Chan, J. C. N., Davis, T. M. E., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06812-4
“Additionally, type 2 diabetes is associated with an accelerated decline in muscle mass [51] and strength [52], with sarcopenia emerging as an important comorbidity, particularly in older adults [53].”
Self-citation
Metadata
- Authors
- Ferrari, U., Then, C., Rottenkolber, M., Selte, C., Seissler, J., Conzade, R., Linkohr, B., Peters, A., Drey, M., & Thorand, B.
- Affiliations
- LMU Klinikum (DE)
- Helmholtz Munich (DE)
- Corresponding author
- Ferrari, Uta
- ORCID
- Venue
- Acta Diabetologica
- Published
- 2020-04-04
- Volume
- 57
- Issue
- 9
- Pages
- 1057-1063
- ISSN
- 0940-5429 (ISSN-L)
- 1432-5233
- OpenAlex
- W3014427335
- Cited by
- 52
- References
- 31
- Citations by year
- 2026: 3 · 2025: 12 · 2024: 7 · 2023: 14 · 2022: 7 · 2021: 8 · 2020: 1
- FWCI
- 4.51
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Acta Diabetologica (publishedVersion)
- PubMed (publishedVersion)
- Site cant be reached (submittedVersion, other-oa)
- Funders
- Bundesministerium für Bildung und Forschung (FKZ 01ET0713, 01ET1003A)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, insulin therapy, skeletal muscle mass, muscle strength, physical performance, older adults, muscle mass loss, grip strength, Timed Up and Go test, skeletal muscle index, KORA-Age study
- MeSH terms
- Aged, Aged, 80 and over, Diabetes Mellitus, Type 2, Postural Balance, Female, Follow-Up Studies, Germany, Humans, Insulin, Longitudinal Studies, Male, Risk Factors, Time and Motion Studies, Exercise, Geriatric Assessment, Muscle, Skeletal, Hand Strength, Muscle Strength, Sarcopenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.